Obese versus non-obese patients with type 2 diabetes: Patient-reported outcomes and utility of weight change

Current Medical Research and Opinion

Volumn 23, Issue 9, 2007, Pages 2051-2062

  Matza, Louis S ^a   Yurgin, Nicole ^b   Boye, Kristina S ^b   Malley, Karen ^c   Shorr, Jodi M ^a  

^a UBC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Malley Research Programming Inc   (United States)

Author keywords

Obesity; Patient reported outcomes (PROs); Type 2 diabetes; Utilities

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; QUESTIONNAIRE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; CASE CONTROL STUDY; INTERVIEW; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INTERVIEWS; MALE; MIDDLE AGED; OBESITY; TREATMENT OUTCOME;

EID: 36048986689     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X219454     Document Type: Article

References (79)

1. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care 2003;30:465-91
2. Bailey CJ. Drugs on the horizon for diabesity. Curr Diab Rep 2005;5:353-9
3. Bulpitt CJ, Palmer AJ, Battersby C, et al. Association of symptoms of type 2 diabetic patients with severity of disease, obesity, and blood pressure. Diabetes Care 1998;21:111-15
4. Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004;65(Suppl 1):S23-7
5. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003;2:33-47
6. Scheen AJ. Treatment of diabetes in patients with severe obesity. Biomed Pharmacother 2000;54:74-9
7. Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diabetes Metab 1998;24:116-23
8. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999;22:1266-72
9. de Lusignan S, Sismanidis C, Carey IM, et al. Trends in the prevalence and management of diagnosed type 2 diabetes 1994-2001 in England and Wales. BMC Fam Pract 2005;6:13
10. Ford ES, Mokdad AH, Giles WH, et al. Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors. Obes Res 2005;13:118-22
11. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004;291:2847-50
12. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31
13. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;282:1519-22
14. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000;23:1278-83
15. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-200
16. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9
17. Sullivan PW, Morrato EH, Ghushchyan V, et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care 2005;28:1599-603
18. Swan G. Findings from the latest National Diet and Nutrition Survey. Proc Nutr Soc 2004;63:505-12
19. Centers for Disease Control and Prevention (CDC). Prevalence of overweight and obesity among adults with diagnosed diabetes - United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep 2004;53:1066-8
20. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997;20:1744-66
21. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
22. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
23. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
24. Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obes 1985;9:147-53
25. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
26. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
27. Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health 2001;4:392-400
28. Zhou H, Isaman DJ, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005;28:2856-63
29. Lee AJ, Morgan CL, Morrissey M, et al. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005;22:1482-6
30. Lean ME, Powrie JK, Anderson AS, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990;7:228-33
31. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-504
32. Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987;147:1749-53
33. Feeny D, Barr RD, Furlong W, et al. Quality of life of the treatment process in pediatric oncology: an approach to measurement. In: Osaba D, ed. Effect of Cancer on Quality of Life. Boca Raton, FL: CRC Press, 1991
34. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2:113-27
35. Patrick DL, Chiang YP. Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges. Med Care 2000;38 (Suppl 9):II14-25
36. Torrance GW, Furlong W, Feeny D. Health utility estimation. Expert Rev Pharmacoeconomics Res 2002;2:99-108
37. Gafni A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res 1994;29:207-24
38. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30
39. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989;5:559-75
40. Brandle M, Herman WH. The CORE Diabetes Model. Curr Med Res Opin 2004;20 (Suppl 1):S1-3
41. Gold MR, Siegel JE, Russell LB, et al., eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996
42. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003;6:9-17
43. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-64
44. Herman WH, Hoerger TJ, Brandie M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-32
45. McEwan P, Peters JR, Bergenheim K, et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006;22:121-9
46. Palmer AJ, Roze S, Lammert M, et al. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Curr Med Res Opin 2004;20 (Suppl 1):S41-51
47. Warren E, Weatherley-Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8:1-57
48. Wee CC, Hamel MB, Davis RB, et al. Assessing the value of weight loss among primary care patients. J Gen Intern Med 2004;19:1206-11
49. Carey MP, Jorgensen RS, Weinstock RS, et al. Reliability and validity of the appraisal of diabetes scale. J Behav Med 1991;14:43-51
50. Grootenhuis PA, Snoek FJ, Heine RJ, et al. Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 1994;11:253-61
51. Brooks R, Rabin R, de Charro F, eds. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht: Kluwer Academic Publishers, 2003
52. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
53. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43
54. Krabbe P, Weijnen T. Guidelines for analysing and reporting EQ-5D outcomes. In: Brooks R, Rabin R, de Charro F, eds. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Dordrecht: Kluwer Academic Publishers 2003
55. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires, 2nd edn. New York: Oxford University Press, 1996
56. Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf) 2005;27:156-64
57. Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458-63
58. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). UK Prospective Diabetes Study Group. Diabetes Care 1999;22:1125-36
59. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CD, et al., eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Washington, DC: Le Jacq Publishing, 1984:170-83
60. Chassany O, Dimenas E, Dubois D, et al. PGWBI User Manual. Lyon, France: MAPI Research Institute, 2004
61. Leonardson GR, Daniels MC, Ness FK, et al. Validity and reliability of the general well-being schedule with northern plains American Indians diagnosed with type 2 diabetes mellitus. Psychol Rep 2003;93:49-58
62. Matza LS, Secnik K, Rentz AM, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual Life Res 2005;14:735-47
63. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998;48:25-36
64. Secnik K, Matza LS, Cottrell S, et al. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med Decis Making 2005;25:56-70
65. Bass EB, Steinberg EP, Pitt HA, et al. Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease. Med Decis Making 1994;14:307-14
66. Cook J, Richardson J, Street A. A cost utility analysis of treatment options for gallstone disease: methodological issues and results. Health Econ 1994;3:157-68
67. Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Med Care 1989;27 (Suppl 3): S190-204
68. Johnson JA, Coons SJ, Ergo A, et al. Valuation of EuroQOL (EQ-5D) health states in an adult U.S. sample. Pharmacoeconomics 1998;13:421-33
69. Stalmeier PF. Discrepancies between chained and classic utilities induced by anchoring with occasional adjustments. Med Decis Making 2002;22:53-64
70. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9
71. Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Obes Res 2005;13:1849-63
72. Wardle J, Waller J, Jarvis MJ. Sex differences in the association of socioeconomic status with obesity. Am J Public Health 2002;92:1299-304
73. Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model. Obes Rev 2000;1:121-6
74. Groessl EJ, Kaplan RM, Barrett-Connor E, et al. Body mass index and quality of well-being in a community of older adults. Am J Prev Med 2004;26:126-9
75. Hakim Z, WoIf A, Garrison LP. Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics 2002;20:393-404
76. Kortt MA, Clarke PM. Estimating utility values for health states of overweight and obese individuals using the SF-36. Qual Life Res 2005;14:2177-85
77. Trakas K, Oh PI, Singh S, et al. The health status of obese individuals in Canada. Int J Obes Relat Metab Disord 2001;25:662-8
78. Torrance GW. Preferences for health outcomes and cost-utility analysis. Am J Manag Care 1997;3:S8-S20
79. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd edn. Oxford, UK: Oxford University Press, 2000